Brief: Icecure Medical Reports First Half 2023 Results
14/08/2023 13:10
Aug 14 (Reuters) - Icecure Medical Ltd ICCM.O :
* ICECURE MEDICAL REPORTS FIRST HALF 2023 FINANCIAL &
OPERATIONAL
RESULTS: GLOBAL ADOPTION OF CRYOABLATION TECHNOLOGY GAINING
MOMENTUM
* ICECURE MEDICAL: AWAITS FDA'S RESPONSE TO ITS REGULATORY
FILING
FOR EARLY-STAGE LOW RISK BREAST CANCER IN PATIENTS WHO ARE AT
HIGH RISK FOR SURGERY
Source text for Eikon: ID:nPn59XhlSa
Further company coverage: ICCM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Icecure Medical
See all newsIcecure Medical Ltd reports results for the quarter ended June 30 - Earnings Summary
Israel's IceCure Medical H1 revenue rises on higher system, probe sales
Brief: Icecure Sio Petitions Nccn To Include Cryoablation In Breast Cancer Treatment Guidelines, Citing Icecure's FDA Clearance Of Prosense®
NASDAQ RESUMED AT 09:55 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:45 AM